Dupilumab for atopic children with eosinophilic esophagitis: A case series

Abstract

Background

The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option.

Methods

In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis.

Results

We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients.

Conclusion

Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.